Recipharm AB (publ) operates as a pharmaceutical contract development and manufacturing company in Sweden, the United Kingdom, Italy, Germany, France, India, Spain, Portugal, and internationally. It operates through four segments: Advanced Delivery Systems (ADS), Manufacturing Steriles (MFG-S), Manufacturing Solids & Others (MFG-SO), and Development & Licensing (D&L). The ADS segment develops and manufactures inhalation products and devices, including integrated drug solutions, medical check valves, and injection devices. The MFG-S segment manufactures sterile products using lyophilisation and blow-fillseal technologies. The MFG-SO segment manufactures non-sterile products, such as tablets, capsules, semi-solids, liquids, and powders. The D&L segment provides pharmaceutical development services, including preclinical and formulation development, and clinical trial material services; manages patents, technologies, and drug product rights; and develops and manufactures drug substance. It also offers packaging products comprising bottles, blisters, stick-packs, vials, ampoules, syringes, pouches, and patches; and online vendor managed inventory solutions. The company was founded in 1994 and is headquartered in Stockholm, Sweden.